⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL134414 | 0.75 | — | — | |
| SCHEMBL12006677 | 0.70 | — | — | |
| SCHEMBL11367223 | 0.67 | — | — | |
| SCHEMBL8292436 | 0.67 | — | — | |
| SCHEMBL1270866 | 0.67 | TSHR (0.30) | — | |
| SCHEMBL8401711 | 0.67 | — | — | |
| SCHEMBL1270865 | 0.67 | TSHR (0.30) | — | |
| SCHEMBL133563 | 0.64 | — | — | |
| SCHEMBL29757 | 0.64 | — | — | |
| SCHEMBL18513525 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180932-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | NESTLE SA (CH) | 2024-06-06 | — | — | US | claimed |
| EP-4313017-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | Société des Produits Nestlé S.A. (CH) | 2024-02-07 | — | — | EP | claimed |
| US-20240010589-A1 | SUBSTITUTED RESORCINOL COMPOUNDS AS AMPK ACTIVATORS, COMPOSITIONS, METHODS AND USES THEREOF | NESTLE SA (CH) | 2024-01-11 | — | — | US | claimed |
| US-20230414638-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | NESTLE SA (CH) | 2023-12-28 | — | — | US | claimed |
| CN-116981452-A | Substituted resorcinol compounds for the management of aging and related disorders | 雀巢产品有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-116761791-A | Substituted resorcinol compounds as AMPK activators and uses thereof | 雀巢产品有限公司 | 2023-09-15 | — | — | CN | claimed |
| CN-116744911-A | Substituted resorcinol compounds as AMPK activators, compositions, methods and uses thereof | 雀巢产品有限公司 | 2023-09-12 | — | — | CN | claimed |
| US-20230026772-A1 | DIBENZOPYRAN AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2023-01-26 | — | — | US | claimed |
| CN-114727979-A | Dibenzopyran AMPK activator compounds, compositions, methods and uses thereof | 雀巢产品有限公司 | 2022-07-08 | — | — | CN | claimed |
| WO-2021105075-A1 | DIBENZOPYRAN AMPK ACTIVATOR COMPOUNDS, COMPOSITIONS, METHODS AND USES THEREOF | Société des Produits Nestlé S.A. (CH) | 2021-06-03 | — | — | WO | claimed |
| US-20240180932-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | NESTLE SA (CH) | 2024-06-06 | — | — | US | disclosed |
| EP-4313017-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS IN THE MANAGEMENT OF AGEING AND RELATED DISORDERS | Société des Produits Nestlé S.A. (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-20240010589-A1 | SUBSTITUTED RESORCINOL COMPOUNDS AS AMPK ACTIVATORS, COMPOSITIONS, METHODS AND USES THEREOF | NESTLE SA (CH) | 2024-01-11 | — | — | US | disclosed |
| US-20230414638-A1 | SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF | NESTLE SA (CH) | 2023-12-28 | — | — | US | disclosed |
| CN-116981452-A | Substituted resorcinol compounds for the management of aging and related disorders | 雀巢产品有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20110135646-A1 | Genes of an Otitis Media Isolate of Nontypeable Haemophilus influenzae | NATIONWIDE CHILDREN'S HOSPITAL, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010077323-A2 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING INFLAMMATORY BOWEL DISEASE AND RELATED DISORDERS | THE JOHNS HOPKINS UNIVERSITY (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-2102350-A2 | THE GUT MICROBIOME AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR AN OBESITY RELATED DISORDER | Washington University in St. Louis (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2008076696-A2 | THE GUT MICROBIOME AS A BIOMARKER AND THERAPEUTIC TARGET FOR TREATING OBESITY OR AN OBESITY RELATED DISORDER | WASHINGTON UNIVERSITY IN ST. LOUIS (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20060194755-A1 | Compositions and methods for regulating an immune response in a subject | INNATE PHARMA, S.A.S. (FR) | 2006-08-31 | — | — | US | disclosed |